A Study of IBI362 in Participants With Type 2 Diabetes

NCT05606913 on ClinicalTrials.gov · last registry update 2024-08-23

Finished 26 January 2024, after enrolling 731 people. Primary outcome, as filed: HbA1c change from baseline at week 28. dulaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: dulaglutide
Trulicity
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Sponsor type: Industry
Enrollment: 731
Started: 2023-01-06
Primary completion: 2024-01-26 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

HbA1c change from baseline at week 28

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.